These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 19645779)

  • 1. Fulvestrant in advanced breast cancer following tamoxifen and aromatase inhibition: a single center experience.
    Wang J; Jain S; Coombes CR; Palmieri C
    Breast J; 2009; 15(3):247-53. PubMed ID: 19645779
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Endocrine response after prior treatment with fulvestrant in postmenopausal women with advanced breast cancer: experience from a single centre.
    Cheung KL; Owers R; Robertson JF
    Endocr Relat Cancer; 2006 Mar; 13(1):251-5. PubMed ID: 16601292
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fulvestrant ('Faslodex') in heavily pretreated postmenopausal patients with advanced breast cancer: single centre clinical experience from the compassionate use programme.
    Mlineritsch B; Psenak O; Mayer P; Moik M; Namberger K; Hauser-Kronberger C; Greil R
    Breast Cancer Res Treat; 2007 Nov; 106(1):105-12. PubMed ID: 17295045
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fulvestrant in women with advanced breast cancer after progression on prior aromatase inhibitor therapy: North Central Cancer Treatment Group Trial N0032.
    Ingle JN; Suman VJ; Rowland KM; Mirchandani D; Bernath AM; Camoriano JK; Fishkin PA; Nikcevich DA; Perez EA;
    J Clin Oncol; 2006 Mar; 24(7):1052-6. PubMed ID: 16505423
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fulvestrant in heavily pretreated metastatic breast cancer: is it still effective as a very advanced line of treatment?
    Safra T; Greenberg J; Ron IG; Ben-Yosef R; Inbar M; Sarid D; Yaal-Hahoshen N
    Isr Med Assoc J; 2008 May; 10(5):339-43. PubMed ID: 18605354
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fulvestrant in heavily pre-treated patients with advanced breast cancer: results from a single compassionate use programme centre.
    Catania C; Ascione G; Adamoli L; De Pas T; Medici M; Franceschelli L; Verri E; Magni E; Sanna G; Torrisi R; Goldhirsch A; Nolè F
    Breast Cancer Res Treat; 2007 Nov; 106(1):97-103. PubMed ID: 17260095
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sensitivity to further endocrine therapy is retained following progression on first-line fulvestrant.
    Robertson JF; Howell A; Gorbunova VA; Watanabe T; Pienkowski T; Lichinitser MR
    Breast Cancer Res Treat; 2005 Jul; 92(2):169-74. PubMed ID: 15986127
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fulvestrant versus anastrozole for the treatment of advanced breast carcinoma in postmenopausal women: a prospective combined analysis of two multicenter trials.
    Robertson JF; Osborne CK; Howell A; Jones SE; Mauriac L; Ellis M; Kleeberg UR; Come SE; Vergote I; Gertler S; Buzdar A; Webster A; Morris C
    Cancer; 2003 Jul; 98(2):229-38. PubMed ID: 12872340
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fulvestrant ('Faslodex') in pre-treated patients with advanced breast cancer: a single-centre experience.
    Steger GG; Bartsch R; Wenzel C; Pluschnig U; Hussian D; Sevelda U; Locker GJ; Gnant MF; Jakesz R; Zielinski CC
    Eur J Cancer; 2005 Nov; 41(17):2655-61. PubMed ID: 16230005
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Response to fulvestrant in heavily pretreated postmenopausal women: a single-center experience.
    Franco S; Perez A; Tan-Chiu E; Frankel C; Vogel CL
    Breast Cancer Res Treat; 2004 Nov; 88(2):103-8. PubMed ID: 15564793
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A comparison of fulvestrant and the third-generation aromatase inhibitors in the second-line treatment of postmenopausal women with advanced breast cancer.
    Dodwell D; Vergote I
    Cancer Treat Rev; 2005 Jun; 31(4):274-82. PubMed ID: 15908126
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Additive antitumor effect of aromatase inhibitor letrozole and antiestrogen fulvestrant in a postmenopausal breast cancer model.
    Jelovac D; Macedo L; Goloubeva OG; Handratta V; Brodie AM
    Cancer Res; 2005 Jun; 65(12):5439-44. PubMed ID: 15958593
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Double-blind, randomized placebo controlled trial of fulvestrant compared with exemestane after prior nonsteroidal aromatase inhibitor therapy in postmenopausal women with hormone receptor-positive, advanced breast cancer: results from EFECT.
    Chia S; Gradishar W; Mauriac L; Bines J; Amant F; Federico M; Fein L; Romieu G; Buzdar A; Robertson JF; Brufsky A; Possinger K; Rennie P; Sapunar F; Lowe E; Piccart M
    J Clin Oncol; 2008 Apr; 26(10):1664-70. PubMed ID: 18316794
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combination anastrozole and fulvestrant in metastatic breast cancer.
    Mehta RS; Barlow WE; Albain KS; Vandenberg TA; Dakhil SR; Tirumali NR; Lew DL; Hayes DF; Gralow JR; Livingston RB; Hortobagyi GN
    N Engl J Med; 2012 Aug; 367(5):435-44. PubMed ID: 22853014
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fulvestrant in the treatment of postmenopausal women with advanced breast cancer.
    Gradishar W
    Expert Rev Anticancer Ther; 2005 Jun; 5(3):445-53. PubMed ID: 16001952
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Double-blind, randomized trial comparing the efficacy and tolerability of fulvestrant versus anastrozole in postmenopausal women with advanced breast cancer progressing on prior endocrine therapy: results of a North American trial.
    Osborne CK; Pippen J; Jones SE; Parker LM; Ellis M; Come S; Gertler SZ; May JT; Burton G; Dimery I; Webster A; Morris C; Elledge R; Buzdar A
    J Clin Oncol; 2002 Aug; 20(16):3386-95. PubMed ID: 12177098
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Fulvestrant is an effective and well-tolerated endocrine therapy for postmenopausal women with advanced breast cancer: results from clinical trials.
    Vergote I; Robertson JF
    Br J Cancer; 2004 Mar; 90 Suppl 1(Suppl 1):S11-4. PubMed ID: 15094759
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Endocrine approaches for the treatment of early and advanced breast cancer in postmenopausal women.
    Tobias JS
    Int J Biochem Cell Biol; 2004 Nov; 36(11):2112-9. PubMed ID: 15313457
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fulvestrant with or without selumetinib, a MEK 1/2 inhibitor, in breast cancer progressing after aromatase inhibitor therapy: a multicentre randomised placebo-controlled double-blind phase II trial, SAKK 21/08.
    Zaman K; Winterhalder R; Mamot C; Hasler-Strub U; Rochlitz C; Mueller A; Berset C; Wiliders H; Perey L; Rudolf CB; Hawle H; Rondeau S; Neven P
    Eur J Cancer; 2015 Jul; 51(10):1212-20. PubMed ID: 25892646
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Fulvestrant (Faslodex®) for hormone sensitive breast cancer. A review].
    Nagykálnai T; Landherr L; Laczó I; Pikó B
    Magy Onkol; 2015 Sep; 59(3):251-7. PubMed ID: 26339914
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.